Handelsbanken Fonder AB boosted its position in Johnson & Johnson (NYSE:JNJ) by 290.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,114,004 shares of the company’s stock after purchasing an additional 829,053 shares during the period. Johnson & Johnson comprises approximately 1.3% of Handelsbanken Fonder AB’s holdings, making the stock its 8th largest position. Handelsbanken Fonder AB’s holdings in Johnson & Johnson were worth $156,662,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in JNJ. Capital World Investors lifted its position in Johnson & Johnson by 182.9% in the first quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock valued at $2,779,435,000 after purchasing an additional 13,703,905 shares during the period. Nordea Investment Management AB lifted its position in Johnson & Johnson by 88.0% in the second quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock valued at $2,382,514,000 after purchasing an additional 8,062,204 shares during the period. Wellington Management Group LLP lifted its position in Johnson & Johnson by 10.8% in the first quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock valued at $4,006,895,000 after purchasing an additional 2,968,879 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Johnson & Johnson by 7.7% in the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock valued at $3,871,753,000 after purchasing an additional 2,118,870 shares during the period. Finally, Capital International Investors lifted its position in Johnson & Johnson by 13.6% in the first quarter. Capital International Investors now owns 16,726,965 shares of the company’s stock valued at $2,193,411,000 after purchasing an additional 2,004,688 shares during the period. Hedge funds and other institutional investors own 67.44% of the company’s stock.
A number of equities research analysts recently commented on the stock. Cantor Fitzgerald restated a “buy” rating and issued a $168.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 target price for the company. in a report on Tuesday, July 7th. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the company from $161.00 to $164.00 in a report on Monday, July 20th. Finally, Raymond James increased their target price on shares of Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a report on Friday, July 17th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $163.00.
JNJ stock traded up $0.34 during midday trading on Tuesday, hitting $148.69. The stock had a trading volume of 216,478 shares, compared to its average volume of 8,504,898. The firm has a market cap of $390.58 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 3.27 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The company’s 50-day moving average price is $149.29 and its 200 day moving average price is $144.17.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion during the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. Johnson & Johnson’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.58 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 7.85 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.01 dividend. The ex-dividend date of this dividend was Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.72%. Johnson & Johnson’s payout ratio is currently 46.54%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.